All In Biotech

Drug Trial Radar · NCT04347005

The Study is Designed to Evaluate Single Ascending Doses of AR882 in Healthy Adult Males

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Rising Dose Study of AR882, a Potent Uricosuric Agent, in Healthy Adult Male Volunteers

Last checked: Nov 19, 2026Latest source record: Nov 16, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

64

Actual

Start

Jan 22, 2019

Primary completion

Jul 31, 2019

Study completion Jul 31, 2019

Sponsor

Lead sponsor
Arthrosi TherapeuticsIndustry
Sponsor type
Industry
First posted
Apr 15, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A randomized, double-blind, placebo-controlled, single ascending dose study of AR882 in healthy adult males.

Conditions

  • Healthy Volunteers

Interventions

  • Cohort 1: AR882Drug

    Single dose of AR882 or matching placebo

  • Cohort 2: AR882Drug

    Single dose of AR882 or matching placebo

  • Cohort 3: AR882Drug

    Single dose of AR882 or matching placebo

  • Cohort 4: AR882Drug

    Single dose of AR882 or matching placebo

  • Cohort 5: AR882Drug

    Single dose of AR882 or matching placebo

  • Cohort 6: AR882 Food EffectDrug

    Single dose of AR882 or matching placebo in a fed state

  • Cohort 7: AR882 Solid Oral FormulationDrug

    Single dose of AR882 or matching placebo

  • Cohort 8: AR882 in combination with allopurinolDrug

    Single dose of allopurinol alone and a single dose of AR882 in combination with a single dose of allopurinol

  • Cohort 9: AR882 in combination with febuxostatDrug

    Single dose of febuxostat alone and a single dose of AR882 in combination with a single dose of febuxostat

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the safety profile of AR882 based on incidence of abnormal laboratory findingsTime frame: 8 Days
  2. Safety AnalysesTime frame: 8 Days
  3. Safety AnalysesTime frame: 8 Days
  4. Safety AnalysesTime frame: 8 Days
  5. Safety AnalysesTime frame: 8 Days
  6. Safety AnalysesTime frame: 8 Days
  7. Safety AnalysesTime frame: 8 Days
  8. Safety AnalysesTime frame: 8 Days
  9. Safety AnalysesTime frame: 8 Days
  10. Safety AnalysesTime frame: 8 Days
  11. Safety AnalysesTime frame: 8 Days
  12. Safety AnalysesTime frame: 8 Days
  13. Area under the curve (AUC) for plasma AR882Time frame: 6 Days
  14. Time to maximum plasma concentration (Tmax) for AR882Time frame: 6 Days
  15. Maximum plasma concentration (Cmax) for AR882Time frame: 6 Days
  16. Apparent terminal half-life (t1/2) for AR882Time frame: 6 Days
  17. Amount excreted (Ae) into urine for AR882Time frame: 6 Days
  18. Fractional Excretion (FEUA) for AR882Time frame: 6 Days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nucleus Network Pty, Ltd.

    Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.